Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 2026
24.3.2026 10:30:00 EET | Business Wire | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA.
Poster Presentation Details:
Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors”
Abstract Number: 3053
Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST
Session Category: Novel Targets and Pathways
Session: PO.ET09.09
Location: Poster Section 15
For more information and to view the Company’s abstract, visit the AACR Annual Meeting website.
About ASTX295
ASTX295 is a potent, highly selective, potentially best-in-class MDM2 antagonist that has completed a phase I study (NCT03975387) in over 100 patients with advanced solid tumors. Rationally designed to exhibit a short half-life, ASTX295 has demonstrated a compelling safety profile with minimal hematological toxicities, enabling use as a combination therapy.
MDM2 is a clinically validated target for cancer therapy, frequently overexpressed across multiple tumor types. As the primary negative regulator of the p53 tumor suppressor protein, MDM2 inhibition leads to p53 stabilization and re-activation, inducing cell cycle arrest and apoptosis.
Mosaic Therapeutics announced the in-licensing of ASTX295, alongside ASTX029 (an ERK1/2 inhibitor), from Astex Pharmaceuticals in April 2025, and holds full development and commercialization rights.
About MOS101
Plans for a Phase 1b/2a study evaluating the combination of ASTX295 with olaparib (an approved PARP inhibitor) for patients with biomarker-selected solid tumors are being finalized.
About Mosaic Therapeutics
Mosaic Therapeutics is an oncology therapeutics company building the category leader in Synergistic Precision Oncology. The company’s mission is to tackle cancers with substantial unmet need and few targeted treatment options, by reinventing the traditional approach to discovering and developing novel combination medicines.
Born out of pioneering research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active programs across a variety of oncology indications and disease biology pathways.
Mosaic is applying its advanced experimental and computational platform to identify oncology combinations that have synergistic activity in biomarker-defined patient populations. The Company’s pipeline is anchored by ASTX295, an MDM2 antagonist, and ASTX029, an ERK1/2 inhibitor, both in-licensed from Astex Pharmaceuticals in April 2025. Mosaic’s first clinical combination study is expected to commence in early 2027.
LinkedIn: https://linkedin.com/company/mosaic-tx
Website: https://mosaic-tx.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260323556546/en/
Contacts
Thomas Fuchs
CEO, Mosaic Therapeutics
E: info@mosaic-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carta Launches Unified Fund of Funds Solution to Automate LP Workflows and Portfolio Visibility24.3.2026 12:01:00 EET | Press release
Carta, the world’s first fully interconnected system for private capital, today announced its solution for Fund of Funds, a new offering designed to help managers automate LP reporting, eliminate manual document processing, and gain clearer visibility into their underlying portfolio exposure. The product expands a critical link in Carta’s ERP for private capital, bringing LP investment data, fund accounting, and portfolio analytics onto a single platform, while more deeply connecting allocators with the GP ecosystem. Fund of Funds represents a critical and growing segment of the private capital ecosystem, projected to reach $450 billion by 2033 as investors seek diversified exposure to private markets. Yet, operating a fund of funds remains highly complex. Managers sit at a unique intersection of the ecosystem, investing as LPs across multiple funds while also serving as GPs to their own investors. As a result, teams are forced to navigate dozens or more of LP portals, manually process
Meeting Rising AI Expectations and Removing Friction Key to Meeting Needs of B2B Buyers Across Europe24.3.2026 12:00:00 EET | Press release
According to a new European study1 of 550 business buyers commissioned by TreviPay, the global B2B payments invoicing and payments network, friction in the B2B buying process in the form of slow onboarding and inconsistent invoicing along with rising expectations for AI-enabled processes are where businesses are experiencing threats to loyalty beyond price. “Across Europe and the UK, finance teams are navigating economic pressure, regulatory complexity and rising buyer expectations,” said Inez Berkhof-Hollander, TreviPay’s Vice President of EMEA. “Our research shows payment and invoicing experiences now play a decisive role in supplier selection.” Top Three European Market Expectations in 2026 1. More AI-driven purchasing options vary by country Nearly 8 in 10 business buyers always or often use AI technologies in B2B purchasing and payment processes; a significant shift from previous years. AI is seen primarily as a means to improve decision-making through data insights (20%), strengt
OCTO and Volkswagen Group Info Services AG Form Partnership for Fleet Data Integration24.3.2026 11:00:00 EET | Press release
OCTO, a leading company in the field of telematics, data analytics and AI-driven solutions for insurance and fleet management, announces a strategic partnership with Volkswagen Group Info Services AG. The goal of this cooperation is to expand data solutions for fleet operators by directly integrating vehicle data from the brands Volkswagen Passenger Cars, Volkswagen Commercial Vehicles, Škoda, Seat, Cupra and Audi. Through this partnership, OCTO gains direct access to vehicle data from fleet vehicles of these six Volkswagen brands. This enables innovative mobility services for fleet managers, including maintenance management, theft protection, damage management, fraud detection, driving behavior analysis, activity reports, e-mobility management, corporate car sharing, and many other functions. These services utilize data such as mileage, fuel consumption, EV status, warning messages, and other parameters, without requiring additional hardware installations. Innovation Through Data Inte
Vonage and ServiceNow Expand their Partnership24.3.2026 10:20:00 EET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vonage integration, calls can automatically trigger incident categorisation, initiate ServiceNow Flow Designer subflows, and update issue resolution data in real time, helping to reduce ma
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom